홈/주식/CANF

CANF

USD

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

$1.125+0.055 (5.140%)

실시간 가격

Healthcare

생명공학

이스라엘

가격 차트

Loading Chart...

핵심 지표

시장 지표

기업 기본 정보

거래 통계

시장 지표

시가

$1.070

고가

$1.125

저가

$1.050

거래량

0.01M

기업 기본 정보

시가총액

14.5M

산업

생명공학

국가

Israel

거래 통계

평균 거래량

0.30M

거래소

ASE

통화

USD

52주 범위

저가 $1.02현재가 $1.125고가 $4.69

관련 뉴스

2025년 4월 17일 · 오후 12:55

GlobeNewswire

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

2025년 4월 15일 · 오전 11:08

Analyst Upgrades

D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma with a Buy and maintains $10 price target.

D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target

2025년 4월 14일 · 오후 06:28

GlobeNewswire

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

2025년 4월 14일 · 오후 12:30

GlobeNewswire

Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships

Ramat Gan, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory

Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships

2025년 4월 14일 · 오후 12:00

GlobeNewswire

Can-Fite Reports 2024 Financial Results and Clinical Update

RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and

Can-Fite Reports 2024 Financial Results and Clinical Update

CANF

가격 차트

핵심 지표

시장 지표

기업 기본 정보

거래 통계

52주 범위

관련 뉴스

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships

Can-Fite Reports 2024 Financial Results and Clinical Update

관련 주식

최신 정보 받기